anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a process for preparing Chinese medicine compound dripping pills for treating headache, which belongs to the preparative technical field of Chinese patent medicine. The traditional Chinese medicine and pharmacy for treating the headache has treatment according to syndrome differentiation, and is regarded by people increasingly. However, the ingredients of the Chinese medicinal are complicated, the content of the active ingredients is small, taking effect is slow, and the time of course of treatment is long. The present invention has the technical scheme that the prescription of the dripping pills comprises two portions of medicine and matrices, wherein the medicine comprises 3 portions of notopterygium root extract, 3 portions of ledebouriella root extract, 2 portions of scutellaria root extract and 2 portions of liquorice extract; the matrices are water soluble matrices, which can select one kind or a plurality of kinds from polyethylene glycol 400, polyethylene glycol 6000, sodium stearate or glycerogelatin. The proportion of the medicine to the matrices is 1:0.5 to 2. The present invention has the advantage that according to different properties of the medicines in the prescription, extraction and purification can be carried out by using a steam extraction method, an alcohol extraction method, etc.
Betimol® Ophthalmic Solution is available in concentrations of 0.25 and 0.5 percent. The usual starting dose is one drop of 0.25 percent Betimol® in the affected eye(s) twice a day. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5 percent solution in the affected eye(s) twice a day.

If the intraocular pressure is maintained at satisfactory levels, the dosage schedule may be changed to one drop once a day in the affected eye(s). Because of diurnal variations in intraocular pressure, satisfactory response to the once-a-day dose is best determined by measuring the intraocular pressure at different times during the day.

Since in some patients the pressure-lowering response to Betimol® may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with Betimol® .

Dosages above one drop of 0.5 percent Betimol® twice a day generally have not been shown to produce further reduction in intraocular pressure. If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine, and/or systemically administered carbonic anhydrase inhibitors, such as acetazolamide, can be instituted.
* Background : Dynamic arterial elastance (Eadyn) has been proposed as an indicator of arterial tone that can predict norepinephrine-dependent arterial pressure. Eadyn is calculated using the ratio of respiratory pulse pressure variation (PPV) over the respiratory stroke volume variation (SVV). Guinot et al demonstrated a decrease in the duration of norepinephrine treatment with the use of Eadyn. To date, studies that have validated Eadyn at bedside have used cardiac output (CO) calibrated pulse contour analysis (PiCCO™, Pulsion™) or oesophageal doppler. Such monitoring systems need dedicated and specific arterial line and venous access that may limit their use at bedside. In addition to CO calibrated pulse contour analysis, CO uncalibrated pulse contour analysis has been developed and is considered less invasive. Nevertheless, one limitation of the latter CO monitoring is inaccuracy of CO measurement in patients who are being treated with norepinephrine. These limitations may affect the predictability of Eadyn.
* Purpose : To date, no study has evaluated the ability of Eadyn measured by uncalibrated pulse contour analysis to assess arterial pressure response to a decreased dose of norepinephrine. We tested the hypothesis that Eadyn calculated from uncalibrated pulse contour analysis predicts the arterial-pressure response to a norepinephrine decrease in patients treated with norepinephrine
Currently, Non-Hodgkin Lymphoma (NHL) constitutes 85-90 % of all lymphomas. Clinical treatment of NHL is based on the "4-drug regimen" known as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Rituximab (RTX) is added to increase the effectiveness and selectivity of the treatment and is the first-line standard treatment for NHL patients. However, success is often prevented by the development of drug resistance. In this study, it was aimed to overcome drug resistance by using two novel tumor-targeted derivatives: guanidine-amphiphilic cyclodextrin (ACD) and guanidine-cyclodextrin polymer (PCD) nanoparticles (NP). These constructs display promise in overcoming drug resistance and enhancing the effectiveness of R-CHOP treatment while potentially eliminating the need for corticosteroid. NP were found to be smaller than 200 nm by dynamic light scattering (DLS). Hemolytic activity and cytotoxicity data on L929 cells demonstrated the safety of the newly synthesized CD derivatives. Additional in vitro characterization studies, including surface charge, physical stability, drug loading capacity, drug release profile, and imaging, as well as conventional and 3D cell culture studies were carried out. Compared to drug solutions, the viability of Daudi human lymphoma cells was statistically significantly decreased in both drug-loaded ACD and PCD NP formulations (p < 0.05). Additionally, RTX-conjugated and drug-loaded ACD NPs exhibited the lowest cell viability due to RTX dependent cytotoxicity.
A bioengineering, in particular to develop novel probiotic preparations based on  Bacillus -strain bacteria, which can be used for preventing and treating infectious diseases and disbiosis of a human being, farm animals and birds. The novel strains of  B. subtilis  07 (VKPM No. B-8611) and  B. licheniformis  09 (VKPM No. B-8610) exhibit a broad spectrum of antagonistic activity, high proteolytic and amylase activity and a distinct ability in terms of a lysozim production. Such strains do not compete with each other but enter into synergistic relations in the form of an increased antagonistic action of the biopreparation. The inventive biopreparation comprises the  B. subtilis  07 VKPM No. B-8611 and  B. licheniformis  09 VKPM No. B-8610 strains and a protective medium. Such biopreparation can also contain a solvent and/or filler and exhibits an increased antagonistic activity with respect to a wide range of pathogenic and opportunistic pathogenic microorganisms and a resistance to quite a number of antibiotics.
A neuron regulatory factor (NRF), derived from cells of the central nervous system, is provided. A cytoprotective peptide (CPP) component of NRF is also provided, as are methods of using NRF or its CPP component. NRF comprises a large polypeptide or complex of polypeptides that is distinct from several other known neurotrophic or neuron regulatory factors. The CPP component of NRF is an acidic protein or protein complex whose amino acid sequence is unique among known protein sequences. Both NRF and its CPP component are capable of promoting survival and neurite outgrowth of cultured neurons in vitro, and preventing neuron degeneration and promoting neuron survival in vivo. The CPP component of NRF also exhibits a cytoprotective effect on non-neuronal cells.
Sarcopenia, characterized by the age-related reduction in strength, muscle mass, and physical function, decreases the ability to perform activities of daily living. Physical inactivity and inadequate nutrition are contributing factors to the development of sarcopenia. Resistance training is a safe, viable and effective intervention which increases measures of muscle and bone mass, muscle performance (i.e., strength, endurance) and functional ability in older adults. However, older adults indicate that high costs and difficulty finding training programming and/or facilities are barriers to participating in resistance training. Home-based resistance-band training is safe, effective and serves as a viable alternative to traditional resistance training (i.e., involving free-weights and machine-based equipment). From a healthy aging perspective, resistance-band training elicits similar improvements in strength (primary indicator of sarcopenia) and functional ability compared to traditional resistance training in older adults. In addition to resistance training (involving resistance-bands), creatine and whey protein supplementations have also been shown to have favorable effects on measures of muscle, bone and functional ability in older adults. However, no study has examined the effects of resistance-band training and creatine and whey protein supplementation in older adults.
Fluticasone propionate, the active component of Fluticasone Propionate Nasal Spray, USP is a synthetic corticosteroid having the chemical name S-(fluoromethyl)6α,9-difluoro-11β-17-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate, 17-propionate and the following chemical structure:

Fluticasone propionate is a white to off-white powder with a molecular weight of 500.6, and the molecular formula is C25H31F3O5S. It is practically insoluble in water, freely soluble in dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol.

Fluticasone Propionate Nasal Spray, USP 50 mcg is an aqueous suspension of microfine fluticasone propionate for topical administration to the nasal mucosa by means of a metering, atomizing spray pump. Fluticasone Propionate Nasal Spray, USP also contains microcrystalline cellulose and carboxymethylcellulose sodium, dextrose, 0.02% w/w benzalkonium chloride, polysorbate 80, and 0.25% w/w phenylethyl alcohol, and has a pH between 5 and 7.

It is necessary to prime the pump before first use or after a period of non-use (1 week or more). After initial priming (6 actuations), each actuation delivers 50 mcg of fluticasone propionate in 100 mg of formulation through the nasal adapter. Each 16-g bottle of Fluticasone Propionate Nasal Spray, USP provides 120 metered sprays. After 120 metered sprays, the amount of fluticasone propionate delivered per actuation may not be consistent and the unit should be discarded.
Icatibant injection should be inspected visually for particulate matter and discoloration prior to administration. The drug solution should be clear and colorless. Do not administer if the product contains particulates or is discolored.

Attach the provided 25 gauge needle to the syringe hub and screw on securely. Do not use a different needle. Disinfect the injection site and administer icatibant injection by subcutaneous injection over at least 30 seconds.

Patients may self-administer icatibant injection upon recognition of symptoms of an HAE attack after training under the guidance of a healthcare professional [ see Patient Counseling Information (17)].
In addition to home based exercise program, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in our clinic per week, other sessions will be performed at home.
A multimodal exercise program (balance, flexibility, aerobic, resistance) will take place 3 times/week, each one lasting 1 hour. Participants in this group will follow their habitual diet. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.
A total of 104 patients were included in this study. At the time of scheduling an outpatient colonoscopy, intervention group and control group were randomly assigned using a random-number generator for treatment allocation. The research protocol was explained during the colonoscopy appointment, and patients, when the participants agreed to follow their preparation to the mobile application, were accepted as part of the patient intervention group. A consent form was signed and collected. The nurse responsible for patient education in the endoscopy secretariat informed the patient that this mobile application is an important component of bowel preparation and adhere strictly to the recipes and recommendations. The group who received the standard diet list and applied for their colonoscopy appointments were randomly designated as the control group. Bowel preparation was evaluated during the colonoscopy using the Boston Bowel Preparation Scale (BBPS). Cecal insertion and withdrawal times, polyp detection rate, utilization of the recipe resource, and patients' experiences related to colonoscopy were recorded.

The research team utilized freely available resources from general cookery recipe websites to create the recipes, adapting it to align with the recommendations for a low-residue diet . Recipes were selected based on criteria such as being visually appealing, easy to prepare, and easily modifiable to comply with the low-residue diet. A dietitian examined the recipes to guarantee that the recipes followed low-residue diet guidelines. The colon preparation recommendations have been obtained from free medical information websites on the internet to facilitate adherence to bowel cleansing.
This study evaluated the pharmacokinetics of mesalamine and its major metabolite of mesalamine known as N-acetyl-mesalamine in plasma. Mesalamine is available in different formulations that control the rate at which they are released in the gastrointestinal tract. Three formulations of mesalamine, Pentasa, Apriso, and Lialda, were studied in the crossover phase, while an oral solution formulation of mesalamine was studied in the single-arm phase. Each subject participated in a crossover phase study with one of the three formulations assigned at random using block randomization. Then the subject entered the single-arm phase study. After participation in one crossover phase study and one single-arm phase study, the subject could opt to participate in crossover phase studies using the other formulations also chosen at random until all three formulations were studied. The single-arm phase study was not repeated on returning subjects who participated in more than one crossover phase study.
The acupuncture will be performed within 6 hours after surgery Acupoint: bilateral Hegu (LI4), Zhigou (SJ6), Zusanli (ST36), Shangjuxu (ST37), All acupoints will be taken by tonifying method after obtaining qi, and unilaterally connected to an electroacupuncture instrument for electrical stimulation with a continuous wave frequency of 5 Hz and a stimulation intensity as tolerated by the patient for 30 min each time. Acupuncture stimulation was given every 12 h. The duration of treatment was from postoperative to the fourth postoperative day (d0-d4) or until the patient's first postoperative anal discharge or until the fourth day.
The invention relates to medicine. A method for the provisional diagnosis of lower extremity venous disorders comprises the steps of obtaining an image of the lower extremities, then segmenting the skin surfaces using a segmentation neural network in order to separate said skin surfaces from the background of the image, and transmitting the results to a detection neural network which identifies segments containing affected areas of skin with veins of the lower extremities and delivers a provisional diagnosis. The segments containing affected areas of skin with veins of the lower extremities are then input into a classification neural network to determine the presence of a lower extremity venous disorder. The results of the detection neural network and the classification neural network are compared to determine the presence of a lower extremity venous disorder. If the diagnoses match, then they are compared with threshold values. If the values of the results of the detection and classification neural networks are higher than said threshold values, a result is delivered with a specific diagnosis. The specific diagnosis is used to generate recommendations for the user. The invention provides an increase in the accuracy with which lower extremity venous disorders are diagnosed.
Cardiac arrhythmias such as atrial fibrillation (AF) are recognised to be associated with re-entry or rotors. A rotor is a wave of excitation in the cardiac tissue that wraps around its refractory tail, causing faster-than-normal periodic excitation. The detection of rotor centres is of crucial importance in guiding ablation strategies for the treatment of arrhythmia. The most popular technique for detecting rotor centres is Phase Mapping (PM), which detects phase singularities derived from the phase of a signal. This method has been proven to be prone to errors, especially in regimes of fibrotic tissue and temporal noise. Recently, a novel technique called Directed Graph Mapping (DGM) was developed to detect rotational activity such as rotors by creating a network of excitation. This research aims to compare the performance of advanced PM techniques versus DGM for the detection of rotors using 64 simulated 2D meandering rotors in the presence of various levels of fibrotic tissue and temporal noise. Four strategies were employed to compare the performances of PM and DGM. These included a visual analysis, a comparison of F2-scores and distance distributions, and calculating p-values using the mid-p McNemar test. Results indicate that in the case of low meandering, fibrosis and noise, PM and DGM yield excellent results and are comparable. However, in the case of high meandering, fibrosis and noise, PM is undeniably prone to errors, mainly in the form of an excess of false positives, resulting in low precision. In contrast, DGM is more robust against these factors as F2-scores remain high, yielding F2≥0.931 as opposed to the best PM F2≥0.635 across all 64 simulations.
Systems and methods are provided for pharmaceutical patient assessment. A prescription fill request may be received by a computer. The prescription fill request may include a patient identifier. The computer may utilize the patient identifier to determine whether a patient is eligible for a pharmaceutical patient assessment. If the patient is eligible, the pharmacy computer may transmit a notification of the eligibility to a pharmacy device. The computer may receive, from the pharmacy device, pharmaceutical patient assessment information indicating the pharmaceutical patient assessment was performed.
PROBLEM TO BE SOLVED: To obtain a solid medicinal preparation capable of readily being taken without water, especially a solid preparation capable of quickly being decomposed and dissolved in the oral cavity by making the preparation contain erythritol, a crystalline cellulose and a disintegrator in a medicinal component. SOLUTION: This solid medicinal preparation is composed of a medicinal component [e.g. a nutritive and tonic agent (vitamin A, etc.), an antipyretic analgesic and antiphlogistic agent (aspirin, etc.) and a psychotropic agent (chlorpromazine, etc.)] containing erythritol as one kind of sugaralcohol, a crystalline cellulose obtained by partially depolymerizing α-cellulose and purifying and a disintegrator (e.g. crospovidone). The solid medicinal formulation contains about 0.05-70wt.% of the medicinal component, about 5-90wt.% of erythritol, about 3-50wt.% of the crystalline cellulose and about 1-10wt.% of the disintegrator.  The formulation is especially suitable for preparing of a medicine frequently requiring to be taken without water, such as an antifebrile, an analgesic, an antiphlogistic, an antianxiety agent, an analgesic and expectorant agent and a preventing and curing agent for motion sickness.
- Measurement of intracanal temperature in vivo Healthy patients attending the dental clinics for non-surgical root canal treatment of permanent mandibular first molars will be included in the study after obtaining ethical approval (IRB ethical approval ref. 10/158/2023). Their body temperature will be measured using a non-contact thermometer pointed at the forehead. Any patient with a body temperature higher than 37°C will not be included. The participants will sign a consent form after the procedure is fully explained. Upon rubber dam isolation, access cavity preparation will be performed, and canals will be chemo-mechanically prepared using a ProTaper Gold NiTi rotary system (Dentsply Sirona, Switzerland). Distal canals will be prepared up to the F3.

A four-channel portable thermometer will be used with two K-type thermocouple probes to simultaneously measure both intracanal and intraoral temperatures. The intraoral temperature will be measured by securing the probe in direct contact with the lingual alveolar mucosa under the rubber dam. The intracanal temperature will be measured by another probe inserted inside the distal canal at the mid-root level. The insertion depth will be verified using a preoperative radiograph and a rubber stop. If the probe insertion to that depth is not possible, the tooth will be excluded. Based on a previous study, 20 teeth will be included in the experiment. In each canal, two measurements will be obtained; the first one will be irrigated using a normal saline set at room temperature (RT), and the other measurement will be taken after irrigation using heated temperature (HT) normal saline . The RT irrigation solution will be used while maintaining the ambient temperature of the air-conditioned clinic fixed at 22°C. The HT irrigation solution will be heated using a chairside dental composite heater set at 45°C. The preset temperatures of each irrigation group will be confirmed with 3 repeated measurements.

After securing the thermocouple probe inside the canal, the RT irrigation solution will be applied using a gauge-27 side vented needle. A video camera will be used for recording the change of both intraoral and intracanal temperatures appearing on the digital display of the thermometer for 180 seconds. After 5 min, the canal will be dried, and the HT irrigation solution will be applied repeating the same steps.

The thermocouple probes will be chemically sterilized before each use. From the video recordings, still frames will be extracted at 5-second intervals using the VLC media player plotting the body and intracanal temperature at each time point.
Patients will receive gabapentin taper over 9 days with the option to add divalproex for patients who have a history of seizures or severe withdrawal. Will still undergo CIWA-Ar scoring but will not be administered a benzodiazepine.
Disclosed and claimed are vectors having enhanced expression and methods for making and using them. Enhancement of expression is from substantially co-temporal expression of at least one first nucleic acid molecule and at least one second nucleic acid molecule. The second nucleic acid molecule encodes a transcription factor or a translation factor or a transcription factor and a translation factor. The contemporaneous expression can be from operably linking the first and second nucleic molecules to a single promoter, or from operably linking the first nucleic acid molecule to a first promoter and the second nucleic molecule to a second promoter wherein the first and second promoters function substantially contemporaneously. Thus, the first and second nucleic acid molecules can be at the same locus in the vector, or at different loci. The second nucleic acid molecule can encode: one transcription factor or more than one transcription factor; or one translation factor or more than one translation factor; or at least one transcription factor and at least one translation factor. The transcription factor can be from vaccinia H4L, D6, A7, G8R, A1L, A2L, H5R, or combinations thereof. The translation factor can be from a K3L open reading frame, an E3L open reading frame, a VAI RNA, an EBER RNA, a sigma 3 open reading frame, a TRBP open reading frame, or combinations thereof. The vector can be a poxvirus such as an attenuated poxvirus, e.g., NYVAC, or ALVAC.